ACAD
Acadia Pharmaceuticals Inc.
September 24, 2026 · pre-market
- Rarity
- 5.85
- Peak move
- −21.26%
- Float cap
- $4.3B
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on neurological and rare diseases. It markets NUPLAZID (pimavanserin) in the United States for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide) for Rett syndrome, including in the United States, Canada, and Israel. It also develops product candidates for Alzheimer's disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, and Huntington's disease.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveclinical_readoutAcadia announced Phase 3-enabling topline results from the Phase 2 portion of the RADIANT trial of remlifanserin in Alzheimer's disease psychosis, where the 60 mg dose hit the primary SAPS-H+D endpoint and key secondary CGI-S-ADP (effect size 0.37, nominal p=0.0077) while 30 mg showed minimal improvement, and Acadia will drop the 30 mg arm from ongoing Phase 3 studies.
analyst_ratingOppenheimer reiterated a Market Perform rating on Acadia Pharmaceuticals (ACAD) with a $25.00 price target on September 23, 2026, calling the upcoming Phase 2 RADIANT topline data for remlifanserin in Alzheimer's disease psychosis the key near-term catalyst, expected in September or October.
peer_disclosureSoleno Therapeutics shares rose 13.5% and another 4.7% after hours after Acadia discontinued ACP-101 in Prader-Willi syndrome, leaving Soleno's recently approved Vykat XR as the only FDA-approved treatment for hyperphagia in PWS.
analyst_ratingLeerink said Acadia's ACP-101 primary-endpoint miss in Prader-Willi syndrome was 'disappointing but expected', noting low expectations given an earlier Phase 3 failure, and kept an Outperform rating on the shares.
clinical_readoutAcadia said its 12-week Phase 3 COMPASS PWS trial of intranasal carbetocin (ACP-101) 3.2 mg three times daily in 175 patients aged 5-30 with Prader-Willi syndrome hyperphagia missed its primary endpoint and all secondary endpoints, and Acadia will not investigate intranasal carbetocin further.